Brief: SynAct Pharma Q3 Adjusted EPS SEK -1
24/10/2023 06:32
Oct 24 (Reuters) - SynAct Pharma Q3 adjusted EPS SEK -1. * Q3 net income SEK -31.878 million * Q3 sales SEK 0 * Q3 cash flow from operating activities SEK -14.653 million * Q3 operating expenses SEK 31.692 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development